11 results
The purpose of the study is to investigate whether the cyclodextrin added to the cholecalciferol formulation has an effect on the vitamin D3 availability in the body. Thus, it will be investigated if concentrations of vitamin D3 that are found in…
Primary objective:- To determine whether high dose vitamin D treatment in optic neuritis can reduce axonal loss as measured by OCT. Secondary objectives: - To investigate whether the occurrence of a second attack (defining clinically definite MS) is…
To investigate the effect of suppletion of vitamin D on aspecific musculo-skeletal disorders
The overall main objective is to develop an optimal combination of sensors and techniques to detect major nocturnal seizures with high sensitivity and specificity in an extramural setting. The study we present here (which is phase 2 out of 3 of the…
Primary objective: To assess the efficacy of Vigantol oil versus placebo as add-on therapy in subjects with relapsing-RemittingMultiple sclerosis receiving treatment with Rebif.Secondary objective:To assess changes on clinical parametersto assess…
We aim to assess the effect of high-dose vitamin D supplementation on non-specific musculoskeletal complaints in non-Western vitamin D-deficient immigrants and to determine whether improvement of mood is associated with this effect.
The primary objective of this study is to determine the efficacy of vitamin D supplementation on the severity of PN in patients with multiple myeloma.
The main objective is to study the effect of vitamin D supplementation on insulin sensitivity in patients with gestational diabetes mellitus.
The aim of this study is to investigate the effect of different doses of vitamin D on postprandial leukocyte activation markers, oxidative stress and arterial stiffness in vitamin D deficient females.
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC.This study aims to explore whether blockade of Transforming…
Safety Run-in (SRI) part:To confirm the recommended phase 2 dose (RP2D) of NIS793 or any other investigational drug(s), in combination with SOC anti-cancer therapy. In protocol amendment 1, an arm with tislelizumab has been added. In this arm, the…